Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Kezar Life Sciences, Inc. (KZR) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -16,560,000 | 33.67 M | 221.24 M | 206.95 M | |
| 2022 | -19,192,000 | 29.7 M | 299.57 M | 285.72 M | |
| 2021 | -48,838,000 | 21.06 M | 217.93 M | 211.65 M | |
| 2020 | -15,764,000 | 10.86 M | 151.84 M | 144.81 M | |
| 2019 | -8,587,000 | 11.47 M | 89.51 M | 81.13 M |